spacer
home > ebr > summer 2019 > the adc jigsaw
PUBLICATIONS
European Biopharmaceutical Review

The ADC Jigsaw

The decades-old war on cancer has yet to be won. While progress has been significant in many indications, mortality rates for some of the most difficult to treat solid tumour types have not improved substantially since the 1970s. For oesophagus and lung cancer, 10-year survival statistics have shown an increase of less than 10%, and pancreatic cancer has shown no improvement at all (1). Furthermore, even in cancers such as melanoma, breast, and uterine where survival rates have improved, more efficacious treatments with fewer debilitating side effects are needed.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Jenny Thirlway leads Iksuda’s ADC programmes, including the preclinical demonstration of Iksuda’s proprietary PermaLink® conjugation chemistry, the exemplification of novel toxin platforms, and the evaluation of partnered antibodies/ alternative scaffolds, focused on the development of a proofof- concept stage ADC portfolio. Jenny has a post-doctoral background in biochemistry and significant experience in the development of biologics, including antibody-based therapeutics and biosimilars.
spacer
Dr Jenny Thirlway
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Launches ADC ExpressTM Services to Accelerate Pre-clinical Conjugation Candidate Selection

• Provides rapid production of antibody drug conjugates (ADCs) for best candidate selection • Established platform technology to reliably scale target molecules • Reduces time to clinic through comprehensive ADC services from pre-clinical to commercial from a single source
More info >>

White Papers

galenIQ - The smart excipient

BENEO GmbH

galenIQ combines a multitude of outstanding characteristics and is suitable for a wide range of pharmaceutical applications. galenIQ can be used as more than just a bulk excipient. It also serves as an anti-caking agent, anti-humectant agent, stabilizer or oral care and taste agent to mention just a few additional functions.
More info >>

 
Industry Events

CPhI Worldwide

5-7 November 2019, Frankfurt, Germany

Join the World's Largest Pharma Event As it Celebrates its 30th Anniversary! Taking place from 5-7 November 2019 in Frankfurt, Germany, the event will bring together more than 45,000 visiting pharma professionals from around the globe and over 2,500 exhibiting pharma companies from every stage of the pharmaceutical supply chain - from ingredients and machinery to outsourcing services, packaging and more!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement